DMAC (DiaMedica Therapeutics) Momentum Rank: 10 (As of Jul. 31, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAC DiaMedica Therapeutics Inc DMAC
32 GF Score
Price $6.34
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics Momentum Rank?

DiaMedica Therapeutics DMAC -2.91% 32 Momentum Rank is 10 as of Jul. 31, 2026, which is 100% above its 10-year median of 5.00. GuruFocus rates DMAC with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

DiaMedica Therapeutics has the Momentum Rank of 10.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

DiaMedica Therapeutics Momentum Rank Related Terms

DMAC vs XFOR, IKT, LXEO: Momentum Rank Comparison

For the Biotechnology subindustry, DiaMedica Therapeutics's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DiaMedica Therapeutics Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Momentum Rank distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's Momentum Rank falls into.


DMAC
32GF Score
DiaMedica Therapeutics Inc DMAC
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 10 mean?
DiaMedica Therapeutics (DMAC) has a Momentum Rank of 10 as of Jul. 31, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on DiaMedica Therapeutics and its competitors. This is 100% above median its historical median of 5.00. Over the past decade, DiaMedica Therapeutics' Momentum Rank has ranged from 1.00 to 10.00.
Is DiaMedica Therapeutics' Momentum Rank too high?
DiaMedica Therapeutics' current Momentum Rank of 10 is 100% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, DiaMedica Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Momentum Rank compare to XFOR and IKT?
DiaMedica Therapeutics' Momentum Rank of 10 can be compared against companies in the Biotechnology industry. Historically, DiaMedica Therapeutics' own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Momentum Rank is 10, which is 100% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Momentum Rank of 10. The current Momentum Rank is 10, which is 100% above median its 10-year median of 5.00. DiaMedica Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Momentum Rank is 10 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
32GF Score

Get the complete analysis for DMAC

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.34
Price